A few months ago, something unusual happened in my Melbourne-based clinic. It wasn’t a new guideline from a medical college, or a major study presented at a scientific conference. It was a political announcement from the United States. Leucovorin
Soon after President Donald Trump and Health Secretary Robert F. Kennedy Jr publicly talked up leucovorin as a “breakthrough” pathway linked to autism, my waiting room started reflecting the news cycle. Parents arrived with screenshots, video clips, and WhatsApp messages from family overseas.
The question was consistent: “Doctor, should we start leucovorin? Is this finally the answer?”
When you are raising an autistic child, hope is not a luxury, it’s fuel. But hope can also be exploited. Loud claims can create pressure and guilt: “If I don’t try this right now, am I failing my child?”
Families deserve better than hype. They deserve clarity.
Autism: a spectrum, not a single problem with a single fix
Autism is a lifelong neurodevelopmental difference. It affects how a person communicates, relates socially, and experiences the world. Some autistic people speak early; some speak later; some communicate in different ways. Some need significant daily support; others live independently.
Most importantly, autism has no single known cause. Research points to a mix of genetic and environmental influences, and autism presents in many ways, which is exactly why a one-size-fits-all “cure” should always raise eyebrows.
What leucovorin actually is
Leucovorin (also called folinic acid or calcium folinate) is a prescription medicine related to folate (vitamin B9). It has been used for decades, mainly in cancer care (for example, to reduce toxicity from certain chemotherapy medicines) and in specific folate-related blood conditions.
It is not the same as over-the-counter folic acid supplements. And like any medicine, it can have side effects, including tummy upset, rashes, fever and sleep disturbance, which is why it should never be started casually or based on social media dosing advice.
Why “CFD” keeps coming up
The scientific conversation around leucovorin in autism is not about “treating autism.” It is about a small subgroup of children who may have trouble getting enough active folate into the brain.
This condition is called cerebral folate deficiency (CFD). In simple terms, CFD means folate levels inside the brain can be low even when blood folate looks normal. Children with CFD may have developmental delay, seizures, movement or coordination difficulties, and sometimes “autistic features” such as differences in social communication, sensory processing, and repetitive behaviours.
In September 2025, the US FDA announced it had initiated an approval process to expand access to leucovorin calcium tablets for CFD, based on a systematic review of published literature and case reports only.
What “FRAA testing” means in plain language
Parents also hear about something called FRAA (folate receptor alpha autoantibodies). Here’s the simplest way to think about it: the brain has a “doorway” that helps folate get in. In some children, immune proteins may partly block that doorway. A blood test can sometimes detect these antibodies, and the theory is that leucovorin may help bypass part of that blockage for some children. But evidence is more limited in broader groups who have autistic features plus these antibodies
What the studies show and what they do not
Some small studies have reported improvements in areas like language and behaviour in selected children, and that has understandably sparked interest. But small studies can mislead, not because researchers are dishonest, but because early results often look more impressive than what we see when larger trials are done.
Australian experts quoted the overall evidence so far is still preliminary, and larger, rigorous trials are needed before this becomes routine care.
The most important voice for parents: the American Academy of Paediatrics
After the surge in interest, the American Academy of Paediatrics (AAP) released interim guidance toggle 31 October 2025. Their message was clear: the AAP does not recommend routine use of leucovorin for autistic children because the evidence base is still too limited.
The AAP emphasised shared decision-making: if families ask about leucovorin, clinicians should explain current evidence and potential risks, and make sure proven supports continue. They also stated they have no prescribing guidelines for leucovorin “for the indication of autism,” and that if it is prescribed, clinicians should prioritise harm reduction, monitor for adverse effects, and track progress toward family goals.
Where this leaves Australian families
In Australia, leucovorin is listed on the Australian Register of Therapeutic Goods ARTG for its established uses (such as chemotherapy-related indications) and remains a prescription medicine. Any use aimed at autism-related symptoms would generally be outside routine prescribing and should only happen with careful medical supervision, clear goals, and close monitoring.
If you are a parent considering leucovorin, my advice is steady and practical: don’t chase headlines – chase good care. Ask what symptom you’re trying to improve, whether there is a genuine reason to suspect a folate-transport problem, how progress will be measured, what side effects to watch for, and when to stop if benefits aren’t real. And above all, keep the foundations strong, communication supports, learning adjustments, family supports, and therapies tailored to the child. Those remain the heart of autism care, regardless of what is trending politically.
Hope is important. But in medicine, the safest hope is hope grounded in evidence.
READ ALSO: ADHD care: Cultural challenges
